The hits identified in this screen and validated in orthogonal assays should be prioritized for further investigation, with the goal of providing a potent and efficacious therapeutic for patients with neuronopathic GD, GBA1-PD, or other diseases associated with GCase activity defects (113, 114). Here, GBA1 is linked to Parkinson disease.